NARA Discovery
Article Details
← Back to Search Results
Journal Article

Progress in the Identification and Design of Novel Antimicrobial Peptides Against Pathogenic Microorganisms

Shengwei Sun
Probiotics and Antimicrobial Proteins · Vol. 17, Issue 2 · pp. 918-936 · 2025

Abstract

The occurrence and spread of antimicrobial resistance (AMR) pose a looming threat to human health around the world. Novel antibiotics are urgently needed to address the AMR crisis. In recent years, antimicrobial peptides (AMPs) have gained increasing attention as potential alternatives to conventional antibiotics due to their abundant sources, structural diversity, broad-spectrum antimicrobial activity, and ease of production. Given its significance, there has been a tremendous advancement in the research and development of AMPs. Numerous AMPs have been identified from various natural sources (e.g., plant, animal, human, microorganism) based on either well-established isolation or bioinformatic pipelines. Moreover, computer-assisted strategies (e.g., machine learning (ML) and deep learning (DL)) have emerged as a powerful and promising technology for the accurate prediction and design of new AMPs. It may overcome some of the shortcomings of traditional antibiotic discovery and contribute to the rapid development and translation of AMPs. In these cases, this review aims to appraise the latest advances in identifying and designing AMPs and their significant antimicrobial activities against a wide range of bacterial pathogens. The review also highlights the critical challenges in discovering and applying AMPs.

Bibliographic Information

JournalProbiotics and Antimicrobial Proteins
PublisherSpringer
Publication Date2025-04-01
Publication Year2025
Volume17
Issue2
Pages918-936
Document TypeJournal Article
Print ISSN1867-1306
eISSN1867-1314
DOI10.1007/s12602-024-10402-4

Access Information

NARA Access Coverage2009-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12602
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.